Human papillomavirus genotype-specific prevalence across the continuum of cervical neoplasia and cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 24, Issue 1, 2015, Pages 230-240

  Joste, Nancy E ^a   Ronnett, Brigitte M ^b   Hunt, William C ^a   Pearse, Amanda ^a   Langsfeld, Erika ^a   Leete, Thomas ^a   Jaramillo, Maryann ^a   Stoler, Mark H ^c,n   Castle, Philip E ^d,h   Wheeler, Cosette M ^a,e   Kinney, Walter ^f   Norville, Scott ^g   Waxman, Alan ^a   Espey, David ^h   Ramos, Mary ^a   Jenison, Steven ⁱ   Schiffman, Mark ^j   Benard, Vicki ^k   Saslow, Debbie ^l   Kim, Jane J ^m   Cuzick, Jack ^o   Pressley, Giovanna Rossi ^p   English, Kevin ^q   more..

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d Global Cancer Initiative   (United States)

^e UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^f KAISER PERMANENTE   (United States)

^g NEW MEXICO DEPARTMENT OF HEALTH   (United States)

^h CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

ⁱ Community Member ^*  (United States)

^j NATIONAL CANCER INSTITUTE   (United States)

^k ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^l AMERICAN CANCER SOCIETY   (United States)

^m HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

ⁿ UNIVERSITY OF VIRGINIA   (United States)

^o QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^p UNIVERSITY OF NEW MEXICO   (United States)

^q Albuquerque Area Indian Health Board   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CANCER SCREENING; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN TISSUE; MAJOR CLINICAL STUDY; MIDDLE AGED; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; UNITED STATES; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VERY ELDERLY; WART VIRUS; YOUNG ADULT; GENETICS; NEOPLASM; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; RISK FACTOR; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; RISK FACTORS; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84921033623     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-0775     Document Type: Article

References (42)

1. de Sanjose S, Quint WG, Alemany L, Tous S, Alejo M, Bigby SM, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010;11: 1048-56.
2. Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WG, Castle PE. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 2009;10:475-87.
3. Hariri S, Unger ER, Powell SE, Bauer HM, Bennett NM, Bloch KC, et al. HPVIMPACT Working Group. Human papillomavirus genotypes in high-grade cervical lesions in the United States. J Infect Dis 2012 Dec 15;206:1878-86.
4. [Last accessed 22 Feb 2014]. Available from: http://clinicaltrials.gov/ct2/show/NCT00543543
5. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012;30S:12-23.
6. Wheeler CM, Hunt WC, Cuzick J, Langsfeld E, Pearse A, Montoya GD, et al. New Mexico HPV Pap Registry Steering Committee. A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination. Int J Cancer 2013;132:198-207.
7. Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlee F, Hildesheim A, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000;38:357-61.
8. Peyton CL, Gravitt PE, Hunt WC, Hundley RS, Zhao M, Apple RJ, et al. Determinants of genital human papillomavirus detection in a US population. J Infect Dis 2001;183:1554-64.
9. Gravitt PE, Schiffman M, Solomon D, Wheeler CM, Castle PE. A comparison of linear array and hybrid capture 2 for detection of carcinogenic human papillomavirus and cervical precancer in ASCUS-LSIL triage study. Cancer Epidemiol Biomarkers Prev 2008;17:1248-54.
10. Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005;337:76-84.
11. Insinga RP, Liaw KL, Johnson LG, Madeleine MM. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev 2008;17:1611-22.
12. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. ACS-ASCCP-ASCP Cervical Cancer Guideline Committee. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012;62:147-72.
13. Moyer VA. U.S. Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;156:880-91.
14. McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008;9:425-34.
15. Insinga RP, Perez G, Wheeler CM, Koutsky LA, Garland SM, Leodolter S, et al. Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance. Cancer Epidemiol Biomarkers Prev 2011;20:287-96.
16. Wentzensen N, Schiffman M, Dunn T, Zuna RE, Gold MA, Allen RA, et al. Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int J Cancer 2009;125:2151-2158.
17. Castle PE, Schiffman M, Wheeler CM, Wentzensen N, Gravitt PE. Human papillomavirus genotypes in cervical intraepithelial neoplasia grade 3. Cancer Epidemiol Biomarkers Prev 2010;19:1675-81.
18. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and highgrade cervical lesions: a meta-analysis update. Int J Cancer 2007;121: 621-32.
19. Castle PE, Shaber R, La Mere BJ, Kinney W, Fetterman B, Poitras N, et al. Human papillomavirus (HPV) genotypes in women with cervical precancer and cancer at Kaiser Permanente Northern California. Cancer Epidemiol Biomarkers Prev 2011;20:946-53.
20. Porras C, Rodriguez AC, Hildesheim A, Herrero R, Gonzalez P, Wacholder S, et al. Human papillomavirus types by age in cervical cancer precursors: predominance of human papillomavirus 16 in young women. Cancer Epidemiol Biomarkers Prev 2009;18:863-5.
21. Sideri M, Igidbashian S, Boveri S, Radice D, Casadio C, Spolti N, et al. Age distribution of HPV genotypes in cervical intraepithelial neoplasia. Gynecol Oncol 2011;121:510-3.
22. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005;97:1072-9.
23. Schiffman M, Glass AG, Wentzensen N, Rush BB, Castle PE, Scott DR, et al. A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study. Cancer Epidemiol Biomarkers Prev 2011; 20:1398-409.
24. Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001;285:1500-5.
25. Sherman ME, Schiffman MH, Lorincz AT, Manos MM, Scott DR, Kuman RJ, et al. Toward objective quality assurance in cervical cytopathology. Correlation of cytopathologic diagnoses with detection of high-risk human papillomavirus types. Am J Clin Pathol 1994;102:182-7.
26. Darragh TM, Colgan TJ, Cox JT, Heller DS, Henry MR, Luff RD, et al. The lower anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med 2012;136: 1266-97.
27. Guimera N, Lloveras B, Lindeman J, Alemany L, van de Sandt M, Alejo M. The occasional role of low-risk human papillomaviruses 6, 11, 42, 44, and 70 in anogenital carcinoma defined by laser capture microdissection/PCR methodology: results from a global study. Am J Surg Pathol 2013;37:1299-310.
28. Schiffman M, Khan MJ, Solomon D, Herrero R, Wacholder S, Hildesheim A, et al. A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst 2005;97:147-50.
29. Centers for Disease Control and Prevention (CDC). National and state vaccination coverage among adolescents aged 13-17 years-United States, 2012.MMWR Morb Mortal Wkly Rep 2013;62:685-93.
30. Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2.MMWR Morb Mortal Wkly Rep 2013;62:591-5.
31. Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res 2009;2:868-78.
32. Herrero R, Wacholder S, Rodriguez AC, Solomon D, Gonzalez P, Kreimer AR, et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov 2011;1:408-19.
33. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356: 1915-27.
34. Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007;298:743-53.
35. Cuzick J, Myers O, Hunt WC, Robertson M, Joste NE, Castle PE, et al. Population-based cervical screening in the United States: the New Mexico experience 2008-2011.Cancer Epidemiol Biomark Prev 2014; 23:65-73.
36. Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013;105:175-201.
37. Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med 2013;11:227.
38. Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE. Estimates of the timing of reductions in genital warts and high grade cervical intraepithelial neoplasia after onset of human papillomavirus (HPV) vaccination in the United States. Vaccine 2013;31:3899-905.
39. Greer CE, Wheeler CM, Manos MM. Sample preparation and PCR amplification from paraffin-embedded tissues. PCR Methods Appl 1994;3: S113-22.
40. Yemelyanova A, Vang R, Seidman JD, Gravitt PE, Ronnett BM. Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas: utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of the corpus tumor. Am J Surg Pathol 2009;33:914-24.
41. Ansari-Lari MA, Staebler A, Zaino RJ, Shah KV, Ronnett BM. Distinction of endocervical and endometrial adenocarcinomas: immunohistochemical p16 expression correlated with human papillomavirus (HPV) DNA detection. Am J Surg Pathol 2004;28:160-7.
42. Hording U, Daugaard S, Visfeldt J. Adenocarcinoma of the cervix and adenocarcinoma of the endometrium: distinction with PCR-mediated detection of HPV DNA. APMIS 1997;105:313-6.